Bausch Health Co. Inc. (BHC) – Business Wire
-
KBRA Releases Third-Quarter 2023 U.S. Bank Compendium and 2024 Outlook
-
KBRA Releases Second-Quarter 2023 U.S. Bank Compendium
-
KBRA Releases First-Quarter 2023 U.S. Bank Compendium
-
KBRA Releases Fourth-Quarter 2022 U.S. Bank Compendium
-
KBRA Releases Third-Quarter 2022 U.S. Bank Compendium and 2023 Sector Outlook
-
KBRA Releases Second-Quarter 2022 U.S. Bank Compendium – Navigating the Sharpest Fed Tightening Cycle Since Volcker
-
KBRA Releases U.S. Bank 1Q22 Compendium
-
KBRA Releases U.S. Bank 4Q21 Compendium: Remarkable Operating Performance in a Period of Extraordinary Liquidity & Revenue Developments; the Future of Overdrafts
-
KBRA Releases U.S. Bank 3Q21 Compendium and 2022 Outlook
-
Bausch + Lomb: Positive Outcomes for Premium LuxSmart™ Intraocular Lenses, Following One-Year Real-World Experience
-
OcuTerra Strengthens Board of Directors with Three New Key Appointments
-
Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million)
-
Bausch Health Expands Dermatology Cash-Pay Prescription Program to Walgreens Stores Nationwide
-
Kimball Electronics, Inc. Announces Appointment of Additional Director
Back to BHC Stock Lookup